Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Gladstone Institutional Advisory LLC

Gladstone Institutional Advisory LLC lowered its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 11.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,885 shares of the biotechnology company’s stock after selling 9,415 shares during the period. Gladstone Institutional Advisory LLC owned approximately 0.08% of Sarepta Therapeutics worth $8,984,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. MassMutual Private Wealth & Trust FSB boosted its position in Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 156 shares during the period. Sunbelt Securities Inc. lifted its stake in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares in the last quarter. Huntington National Bank boosted its position in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after buying an additional 175 shares during the period. Newbridge Financial Services Group Inc. acquired a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $36,000. Finally, UMB Bank n.a. grew its stake in shares of Sarepta Therapeutics by 105.9% in the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 197 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

SRPT opened at $109.68 on Wednesday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company’s 50-day moving average price is $120.49 and its 200 day moving average price is $125.33. Sarepta Therapeutics, Inc. has a fifty-two week low of $102.15 and a fifty-two week high of $173.25. The firm has a market cap of $10.48 billion, a price-to-earnings ratio of 87.74 and a beta of 0.75.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Robert W. Baird decreased their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics in a research note on Tuesday. They issued a “hold” rating and a $136.00 target price for the company. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $152.00 to $167.00 in a research note on Thursday, November 7th. HC Wainwright reissued a “sell” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, January 30th. Finally, Jefferies Financial Group started coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They set a “buy” rating and a $165.00 target price for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $176.77.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.